科室主要SCI文章

1.Zhu X , Shi W , Tai W , et al. The comparition of biological characteristics and multilineage differentiation of bone marrow and adipose derived Mesenchymal stem cells[J]. Cell & Tissue Research, 2012, 350(2):277-287.

2.Lei W , Fuquan L , Zhendong Y , et al. Interventional treatment of stent restenosis or occlusion after transjugular intrahepatic portosystemic shunt[J]. Journal of Capital Medical University, 2014, 35(1):136-139.

3.He F L , Wang L , Yue Z D , et al. Parallel transjugular intrahepatic portosystemic shunt for controlling portal hypertension complications in cirrhotic patients[J]. World Journal of Gastroenterology, 2014, 20(33):11835-11839.

4.Qiu B , Zhao M F , Yue Z D , et al. Combined transjugular intrahepatic portosystemic shunt and other interventions for hepatocellular carcinoma with portal hypertension[J]. World Journal of Gastroenterology, 2015, 21(43):12439-12447.

5.Fu-Liang, Wang, Hong-Wei, et al. Transjugular intrahepatic portosystemic shunt for severe jaundice in patients with acute Budd-Chiari syndrome[J]. World Journal of Gastroenterology, 2015, 21(8):2413-8.

7Wang L . Establishment of a hepatic cirrhosis and portal hypertension model by hepatic arterial perfusion with 80% alcohol[J]. World Journal of Gastroenterology, 2015, 21(32).

7.Yao J, Zuo L, An G, et al. Risk Factors for Hepatic Encephalopathy after Transjugular Intrahepatic Portosystemic Shunt in Patients with Hepatocellular Carcinoma and Portal Hypertension.[J]. Journal of Gastrointestinal & Liver Diseases Jgld, 2015, 24(3):301-307.

8.Fuliang H , Shan D , Zhibo X , et al. Pathological Predictors of Shunt Stenosis and Hepatic Encephalopathy after Transjugular Intrahepatic Portosystemic Shunt[J]. BioMed Research International, 2016, 2016:1-8.

9.Zhao M , Yue Z , Zhao H , et al. Techniques of TIPS in the treatment of liver cirrhosis combined with incompletely occlusive main portal vein thrombosis[J]. Scientific Reports, 2016, 6:33069.

10.He F , Zhao H , Dai S , et al. Transjugular intrahepatic portosystemic shunt for Budd–Chiari syndrome with diffuse occlusion of hepatic veins[J]. Scientific Reports, 2016, 6:36380.

11.Wang L , Xiao Z , Yue Z , et al. Efficacy of covered and bare stent in TIPS for cirrhotic portal hypertension: A single-center randomized trial[J]. Scientific Reports, 2016, 6:21011.

12.Zhao H , Liu F , Yue Z , et al. Evaluation of mid- and long-term efficacy of shunt limiting for hepatic myelopathy after transjugular intrahepatic portosystemic shunt[J]. Clinics & Research in Hepatology & Gastroenterology, 2016, 40(4):440-446.

13.Qiu B , Li K , Dong X , et al. Transjugular Intrahepatic Portosystemic Shunt for Portal Hypertension in Hepatocellular Carcinoma with Portal Vein Tumor Thrombus[J]. CardioVascular and Interventional Radiology, 2017, 40(9):1372-1382.

14.Zhao H , Liu F , Yue Z , et al. Association of hepatic vein Lipiodol tram-track sign during transcatheter arterial chemoembolization with perioperative death[J]. Journal of International Medical Research, 2017:030006051770414.

15.Wang L , He F , Yue Z , et al. Techniques and long-term effects of transjugular intrahepatic portosystemic shunt on liver cirrhosis-related thrombotic total occlusion of main portal vein[J]. Scientific Reports, 2017, 7(1):10868.

16.Zhao, Hongwei, Fuquan Liu, Zhendong Yue, Lei Wang, Zhenhua Fan, Yanna Liu, Jialiang Hui, Yi Xiang, and Xiaolong Qi. "Transjugular intrahepatic portosystemic shunt for chronic portal vein thrombosis and incidence of hepatic eeplopathy." Int J Clin Exp Med 10, no. 2 (2017): 3486-3493.

17.Qi, Xiaolong, Yu Zhang, Zhenyuan Ning, Yifei Huang, Jialiang Zou, Sizhe Chen, Chuan Liu et al. "Diagnostic Accuracy of Radiomics-based Hepatic Venous Pressure Gradient for Clinically Significant Portal Hypertension in Cirrhosis." 2017.

18.Zhao H , Liu F , Yue Z , et al. Clinical efficacy of transjugular intrahepatic portosystemic shunt in the treatment of hepatopulmonary syndrome[J]. Medicine, 2017, 96(49):e9080.

19.Qi X , Liu F , Li Z , et al. Insufficient accuracy of computed tomography-based portal pressure assessment in hepatitis B virus-related cirrhosis[J]. Journal of Hepatology, 2017:S0168827817322778.

20.Song T , R?Ssle M , He F , et al. Transjugular intrahepatic portosystemic shunt for hepatorenal syndrome: A systematic review and meta-analysis[J]. Digestive and Liver Disease, 2018:S1590865818301373.

21.Hong-Bin L , Zhen-Dong Y , Hong-Wei Z , et al. Pathological Features of Mitochondrial Ultrastructure Predict Susceptibility to Post-TIPS Hepatic Encephalopathy[J]. Canadian Journal of Gastroenterology and Hepatology, 2018, 2018:1-9.

22.Dong J , He F , Wang L , et al. Iodine density Changes in Hepatic and Splenic Parenchyma in Liver Cirrhosis with Dual Energy CT (DECT): A Preliminary Study[J]. Academic Radiology, 2018.

23.Liu F , Ning Z , Liu Y , et al. Development and validation of a radiomics signature for clinically significant portal hypertension in cirrhosis (CHESS1701): a prospective multicenter study[J]. EBioMedicine, 2018.

24.Zhao H , Yue Z , Wang L , et al. Benefits of Early Treatment for Patients with Hepatic Myelopathy Secondary to TIPS: A Retrospective Study in Northern China[J]. Scientific Reports, 2018, 8(1).

25.Qi, Xiaolong, Weimin An, Fuquan Liu, Ruizhao Qi, Lei Wang, Yanna Liu, Chuan Liu et al. "Virtual hepatic venous pressure gradient with CT angiography (CHESS 1601): a prospective multicenter study for the noninvasive diagnosis of portal hypertension." Radiology 290, no. 2 (2018): 370-377.

26.Wu Y F , Wang T , Yue Z D , et al. Stents combined with iodine-125 implantation to treat main portal vein tumor thrombus[J]. World Journal of Gastrointestinal Oncology, 2018, 10(12):496-504.

27.He, Fu-Liang, Chuan Li, Fu-Quan Liu, and Xing-Shun Qi. "Correlation analysis of collagen proportionate area in Budd-Chiari syndrome: A preliminary clinicopathological study." World journal of clinical cases 7, no. 2 (2019): 130.

28.Zhang, Yue, Yi-Fan Wu, Zhen-Dong Yue, Hong-Wei Zhao, Lei Wang, Zhen-Hua Fan, Fu-Liang He, Tao Wang, and Fu-Quan Liu. "Iodine-125 implantation with transjugular intrahepatic portosystemic shunt for main portal vein tumor thrombus." World Journal of Gastrointestinal Oncology 11, no. 4 (2019): 310.

29.Qi, Xiaolong, Yifan Wu, Chuan Liu, Zhendong Yue, Hongwei Zhao, Lei Wang, Xiaoxue Du, Fuliang He, and Fuquan Liu. "Mo1527–Transjugular Intrahepatic Portosystemic Shunt with 7 Mm Covered Stent Reduces Hepatic Encephalopathy Without Losing Shunt Function for Prevention of Portal Hypertension Rebleeding." Gastroenterology 156, no. 6 (2019): S-1332.

30.Qi, Xiaolong, Lei Wang, Fangze Huang, Chuan Liu, Xinlong Lin, Xiangbo Zeng, Yanna Liu, and Fuquan Liu. "Mo1533–Portal Pressure Gradient Measured Immediately After Transjugular Intrahepatic Portosystemic Shunt Placement: Poor in Predicting Rebleeding in Patients with Portal Hypertension." Gastroenterology 156, no. 6 (2019): S-1334.

31.Qi, Xiaolong, Wenda Li, Pinzhu Huang, Xinlong Lin, Xiangbo Zeng, Yanna Liu, Ruizhao Qi, Fuquan Liu, Yu Wang, and Chunqing Zhang. "Von Willebrand factor a non-invasive serum biomarker of portal pressure in cirrhosis: Evidence in human and rodent." In JOURNAL OF HEPATOLOGY, vol. 70, pp. E823-E824. PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS: ELSEVIER SCIENCE BV, 2019.

32. He FL1, Li C2, Liu FQ1, et al.Correlation analysis of collagen proportionate area in Budd-Chiarisyndrome: A preliminary clinicopathological study. World J Clin Cases. 2019 Jan 26;7(2):130-136.